INTRO

Returning to London for it’s landmark fifth year, the must-attend Pharma Integrates event will take place on 15-16 November at the Grange City Hotel, London. Already supported by 70 prestigious speakers and 250 senior industry executives, a top-tier programme of interactive debate led panel discussions will focus on the strategic issues facing the drug manufacturing industry and, once again, play a key role in shaping pharma’s future.

Tackling issues such as the rise of precision medicine, disruptive thinking in pharmaceutical regulation, improving patient compliance, future pharmaceutical supply chains and more, key opinion leaders and senior industry stakeholders will debate and discuss the sector’s most pressing challenges and enable life science leaders to stay current and connected in a stimulating peer-to-peer environment.

The speakers, delegates and sponsors of Pharma Integrates are developers and manufacturers of pharmaceutical and biopharmaceutical products, specialty chemicals, bulk products and raw materials, drug delivery devices, instrumentation and equipment. They also work in universities, research institutes, government agencies, contract research and manufacturing companies, and organisations involved in consultation and market research, finance, regulatory affairs, information technology and patient advocacy.

AGENDA

TUESDAY 15TH NOVEMBER

DAY 1: 12:00 REGISTRATION / 13:45 – 17:35 AFTERNOON PROGRAMME / 17:35 – 19:15 CHAMPAGNE RECEPTION

DAY 1

INTERVIEWS PLUS PLENARY PANEL DISCUSSIONS

Pharma Integrates has expanded its remit and relevance to the greater pharmaceutical industry by introducing key interviews with senior industry leaders to complement the well-established panel debates. The 30-minute interview will include Q & A from the audience. The topics for this interview will be announced shortly.

Citing examples from different therapeutic areas, such as hepatitis C, Alzheimer’s and antibiotics, this session will discuss new development, finance and reimbursement strategies for the pharmaceutical industry. Panellists will focus on topics including moving from a product supplier model to a paid by results scenario, the NGO approach to meeting unmet medical needs, the honest truth about mergers and acquisitions and the disintermediation of the current healthcare pathway.

Panellists include:

Mike Rea, Chief Executive Officer, IDEA Pharma
Harry Stratford Non-Executive Director, Neurocentrx
Richard Seabrook Head of Business Development Innovations, The Wellcome Trust

Pharma Integrates has expanded its remit and relevance to the greater pharmaceutical industry by introducing key interviews with senior industry leaders to complement the well-established panel debates. The 30-minute interview will include Q & A from the audience. The topics for this interview will be announced shortly.

This session will focus on improving R&D performance to deliver better medicines for patients at a fraction of the time and $2bn cost currently associated with bringing a new drug to market.  Novel technologies such as human organs-on-chips, computational biology, artificial intelligence, in silico modelling and predictive drug design hold the promise for more fruitful drug discovery. Meanwhile biomarkers for precision medicine and adaptive clinical trials design could revolutionise drug development. Panellists will discuss how industry needs to assume its own risk — rather than being managed by regulators — and new technologies and processes can be used to streamline groaning workflows. Other issues, such as how partnerships between patient advocacy groups, insurers and payers, healthcare providers, big pharma, biotechs and academia might improve R&D productivity to the benefit of all stakeholders are also up for debate.

Panellists include:

Emma Sceats Chief Executive Officer, CN Bio Innovations
Julien Meissonnier Vice President Science & Technology, Catalent Pharma Solutions
Christoph Heinemann Vice President Strategy & Business Management, Global Biologics, Sanofi

What can industry do to implement disruptive strategies and improve regulatory acceptance? Are pharmaceutical regulators anti-disruption? And, given the current situation, should they be disrupted? Does current regulation really support product and manufacturing innovation and, in that model, where should accountability for risk lie? The panel will discuss whether the pharmaceutical industry can come up with a meaningful, transparent and simple self-regulation model that could make regulators redundant. Be prepared for truly disruptive thinking.

WEDNESDAY 16TH NOVEMBER

DAY 2: 08:30 START – 17:00 CLOSE

DAY 2

PANEL DISCUSSIONS

We’re increasingly hearing about patient centricity in pharma. It’s easier to see how this works in supporting patients to take medicines, but how does patient centricity affect the current pharmaceutical supply chain and manufacturing model? What can we learn from the automotive industry, for example, wherein customers configure requirements and pull requirements from the supply chain? Other sectors, such as food and beverage, FMCGs, etc., provide inspiration for customer-centric product design, which could be incorporated into the pharmaceutical business model. The panel will discuss push versus pull dynamics and whether the current system can be more closely aligned with other consumer-based consumption and lifestyle paradigms.

Facilitated by:

Mark Duman Director Market Development, Intelesant Patient Information Forum

Panellists include:

Gregor Anderson Device & Packaging Design Director, GlaxoSmithKline
Massimo Bresciani R&D, Director Scientific Operations, Research Centre for Pharmaceutical Engineering
Ben Reason Founding Partner & Director, Livework
Bev Nicol Senior Manager, Clinical Supplies Organisation, Pfizer Global Research & Development

Big pharmaceutical companies have painted themselves into a corner. By dropping products once out-of-patent protection and embarking on the wholesale divestment of skilled people and facilities that are crucial to developing properly differentiated products, there is nowhere left to go. So, what is pharmaceutical addiction and what’s the solution? The session will focus on driving down drug development costs, using in silico/ex vivo technologies to dramatically reduce attrition, the benefits of engaging deeply with healthcare professionals and patients, and moving to a production system approach for commercial supply.

Facilitated by:

Hedley Rees Managing Director, Biotech PharmaFlow

Panellists include:

Jesus Zurdo Senior Director Strategic Innovation, Lonza Pharma & Biotech
Minesh Khashu Consultant Neonatologist, NHS & Professor of Perinatal Health, Bournemouth University
Gary Acton Captain, Pirates of Oncology
Graham Cox Principal Consultant, Kasocio

Tackling a wide range of related topics, including patient monitoring, the role of medical devices and drug-device regulation, smart packaging and mHealth, the integration of medical technologies and linking diagnostics to drugs, the panel will address the overriding question of who provides this integrated service to customers in global markets. Is it a direct to patient model, which may be subject to regulatory constraints, and does it rely on channel partners, possibly creating local integration hurdles? Other challenges facing bringing diagnostics to market, such as data, investment and payment, are also up for debate.

Panellists include:

Neil Mesher Chief Executive Officer, Philips UK & Ireland
Piers Mahon Director of Global Alliances, Cancer Commons
Hakim Yadi Chief Executive Officer, Northern Health Science Alliance
Virginia Acha Executive Director – Research, Medical & Innovation, The Association of the British Pharmaceutical Industry (ABPI)

Considering the impact of non-responders, non-adherence and non-refillers, the panel will assess what actually constitutes “non-compliance” and whether or not 25% compliance levels are acceptable for both the industry and patients. The role of smart medicine, payers and devices that can demonstrate compliance will be discussed, as will whether the pharmaceutical industry should invest in behavioural models for compliance/concordance … or whether that’s a topic for provider groups to consider.

Panellists include:

Marco Mohwinckel Global Head Janssen Solutions & Janssen Healthcare Innovation, Janssen
Jon-Paul Sherlock Director, Intelligent Pharmaceutical (Respiratory), AstraZeneca
Cornell Stamoran Vice President, Strategy and Corporate Development, Catalent Pharma Solutions
Louise Righton Global Marketing Operations Manager, 3M Drug Delivery Systems
Yury Rozenman Director Business Development, Qualcomm Life

In a world in which we need to collaborate in groups to be successful as individuals, understanding how to engage with small and large companies, with institutions and patient advocacy organisations has become increasingly important. But it’s not easily done. Despite the non-silo thinking, there are still hurdles to the adoption of new innovative practices and technologies. Is Big Pharma unable to adopt new practices and techniques because of its existing infrastructure? What lessons can we learn from more agile, rapidly growing companies? What can biotech companies learn from Big Pharma — and vice versa — that can be adapted to their specific environments to foster an atmosphere of more liberal thinking?

Facilitated by:

Maureen Coleman Executive Chairman, CN BioInnovations

Panellists include:

Ian Moules Senior Director, Search & Evaluation, Centre for External Innovation, Takeda Pharmaceuticals
Sylvia Lobo Established Products EU Regulatory Cluster Lead, Pfizer
Jonny Ohlson Chief Executive Officer, Touchlight Genetics

Strong revenues are fuelling pipeline growth and will continue to drive R&D, but how long will it last? The well-financed pipeline makes near-term outsourcing prospects look favourable, but record investment in captive capacity means the propensity to outsource isn’t likely to increase. Smaller volume products and payer resistance are also factors. Yet, as sponsors look to simplify their CMO networks and establish preferred/strategic partnerships, the outlook for CDMOs with integrated offerings looks very promising. North American and European CMOs have traditionally dominated the contract manufacturing market for years, going forward, however companies based in emerging countries may play a greater role as they experience sustained demand from domestic pharmaceutical companies and, increasingly, foreign drug developers.

Facilitated by:

Mark Cassidy President API Services, Piramal Healthcare

Panellists include:

Ian Muir Managing Director, Aesica Pharmaceuticals
CordenPharma
David Long Head of Pharma Centre of Expertise and Business Excellence, UCB Pharma
Folker Ruchatz, Heads of Contract Manufacturing Business Biopharmaceuticals, Boehringer Ingelheim

Improving the rate of uptake of innovation is a win-win situation for industry, government, health systems and, most importantly, patients, and several examples exist across the EU and US with the UK’s Accelerated Access Review, the EU’s PRIME and breakthrough designation in the US.

The panel will discuss whether accelerated access systems could be used to test both new technologies and new business models, how they can help to establish specific countries as a destination for pharma/life sciences innovation and, within the UK, what else can industry do to help the government enable the UK to become a world leader in innovation use to deliver significantly better outcomes for NHS patients at an affordable cost.

The panel will also consider the implications of suppliers to the pharmaceutical industry managing more uncertainty over launch dates and product volumes, cross-border deal making and multinational clinical studies.

Panellists include:

James Xue Chairman and Chief Executive Officer, CANbridge Life Sciences
Mike Capaldi Chief Executive Officer, Sunergos Innovations
Mohit Misra Chief Medical Officer & Vice President Health Systems, Aetion
Amanda Begley Director of Innovation and Implementation, UCLPartners

The future pharmaceutical industry will require a connected health ecosystem comprising leaders from the entire healthcare spectrum, including medical device manufacturers, health service providers, pharmaceuticals, payers, application developers and more. The connected health model uses technology to provide remote healthcare that both maximises available resources and provides increased opportunities for consumers to engage with clinicians and better self-manage their care. Encompassing telehealth, data collection and analysis, remote home care and disease and lifestyle management, seamless connectivity, care co-ordination and patient engagement will enable increased efficiencies, reduced costs and improved patient health outcomes. The panel will discuss how the connected health model could address many inefficiencies (work flow management, chronic disease management and patient compliance) and propelling healthcare into the future.

Panellists include:

Thom Van Every Executive Director ‘Hive’ Innovation Unit, ViiV Healthcare
Lizzie Tuckey Medical Director, Bupa UK
Nicola Perrin Head of Policy, Wellcome Trust
Iain Buchan Professor of Public Health Informatics, University of Manchester & Director, Farr Institute
Matthew Bonam Director Intelligent Pharmaceuticals, AstraZeneca

What does the pharmaceutical industry really need, in terms of size, shape and scope from its supply chain, and why is the drug manufacturing sector still investing significantly in capacity when other industries no longer consider this to be a core capability? Topics for debate include how changes in drug production (smaller applications, niche therapies and global supply needs) impact the supply chain, M&A and consolidation, in-house versus outsourced production and whether manufacturing innovation and technologies such as continuous processing or late-stage customization should be driven by pharmaceutical manufacturers or the supplier base. Also on the agenda will be pharma’s service-oriented mindset, out-licensing dossiers to expedite product implementation and comparing pure CMOs with pharma companies offering contract manufacturing services.

Facilitated by:

Howard Marriage Translator and Entrepreneur in Residence, The Francis Crick Institute

Panellists include:

Gregor Kawaletz Chief Commercial Officer, IDT Biologika
Detlef Behrens Head of Strategic Procurement, Helm
Benjamin Breitfeld Head of Sales & Marketing Contract Manufacturing Services, Aristo Pharma
Jian Irish Vice President Strategic Supply Sourcing and Partnerships, Sanofi
Torsten Mau Corporate Vice President Supply Network and Process Management, Boehringer Ingelheim

Serialisation changes how the pharmaceutical industry makes and distributes medicines. Key topics on the agenda for debate include legal issues (FMD, DSCSA) and other key drivers, factors such as process change, equipment requirements, business issues and costs, and data (generation, storage, sharing, ownership and exploitation). Serialisation could also prove to be a key enabling technology for the industry, so the panel will also explore opportunities in smart packaging and eHealth (linking diagnostics, treatments and patient outcomes) and future supply chain issues, including late stage customization, the micro-manufacture of patient-specific drugs and distributed manufacturing locations.

Facilitated by:

Mark Davison Chief Executive Officer, Blue Sphere Health

Panellists include:

Martin FitzGerald Deputy Director General, GIRP – European Healthcare Distribution Association
Neil Lawrence Global Serialisation Champion, Global Manufacturing and Supply, GlaxoSmithKline
Paul Cruise Principal Engineer, Packaging Sci Tech, Global Pharma Technology, Shire Pharmaceuticals
Erik Haeffler Vice President Manufacturing Services & Head of CSR, Recipharm

Driven by an ageing population, globalisation and urbanisation, the level of change in the next 5 years will be greater than the pharmaceutical industry has experienced in the previous 35. A seismic shift is coming that will, for the unprepared, make existing 3-5 year plans redundant. Falling profit margins, greater operating costs, volatile demand forecasts, supply chain disruption, material and people shortages, etc., will have multiple repercussions, and only the resilient will survive. Those who are productively paranoid and have prepared their organisations to become resilient, adopted intelligent risk management and taken their overly complex legislation, systems and procedures back to basics will thrive and prosper. But what are these challenges and how should industry prepare? Let’s start the debate.

Facilitated by:

Martin Lush President, NSF Health Sciences Pharma Biotech Consulting

Panellists include:

Pete Milligan Vice President Clinical Platforms Transformation, GlaxoSmithKline
Stephen Brewis Chief Research Scientist, BT Innovate & Design
Jon Townend Senior Director, ESI Operations & Strategy, Janssen

SPEAKERS

Pharma Integrates 2015 was a resounding success, in excess of 70 speakers contributed on the day, take a look at the line up we have in place for you in 2016.

speakers

View All Speakers

SPONSORS

Pharma Integrates 2016 is proud to present this year’s sponsors

View 2016 Sponsors

REGISTER NOW

Book your ticket to Pharma Integrates 2016 today

Package includes:

  • Access to the full programme of conference sessions and panel debates (both days)
  • Champagne and canapé reception
  • Networking luncheon and refreshment breaks
  • Access to digital member networking group
  • Access to all filmed content post event

Book now to secure our early bird delegate rate of £995 + VAT.

Simply complete the form here and a representative will contact you or call us on +44 (0) 20 8688 3906 or +44 (0) 20 8667 9551.

Discounts are also available for multiple places for a limited period.

VENUE

GRANGE CITY HOTEL

Pharma Integrates 2016 will be held on Tuesday 15th and Wednesday 16th November, 2016 at the Grange City Hotel, London.

The Grange City is a luxury hotel in London near the River Thames, commanding sweeping views over the Tower of London and the iconic Tower Bridge. Reflecting its historic City location, the hotel site incorporates the last remaining section of London’s Roman Wall – which stands undamaged from when it was originally patrolled by Roman sentries.
Popular local attractions close to the hotel in the City of London include the Tower of London, Petticoat Lane Market, and St Katharine Dock.

The nearest underground station is Tower Hill, on District and Circle lines. When you exit the station, turn right and walk along Coopers Row for 50 metres: the hotel is on the right. The DLR Tower Gateway is 2 minutes away.

Special rates for Pharma Integrates 2016 are available.

Demand is high at the venue so we encourage attendees to book accommodation straight away. To book your discounted accommodation now please click here

Alternatively please call +44 (0) 207 863 3700 quoting reference CCT156280 to secure a discounted rate.

LOCATION

8-14 Cooper’s Row,
London
EC3N 2BQ

Phone: +44 (0) 20 7863 3700

View Map

OTHER SERVICES & EVENTS

As well as our headline event, we supply a number of other services and events to the pharmaceutical and nutrition industry, including NHS Market Research and Access Service, Nutrition Integrates and Private Client Events

Read More

STEERING COMMITTEE

Pharma Integrates 2016 is supported by a 22 strong committee of recognised industry experts and leading practitioners

committee-2

View The Committee

PARTNERS

Pharma Integrates 2016 is supported by the following Partners

View All Partners

CONTACT

For all Speaker, Partner, Sponsor & Delegate Enquiries call Life Sciences Index on +44 (0) 20 8667 9551 or +44 (0) 20 8688 3906

Book now to secure our early bird delegate rate of £995 + VAT. The delegate package includes access to the full programme of conference sessions and panel debates, champagne reception, networking luncheon, refreshment breaks and access to all filmed content post event. Simply complete the form below and a representative will contact you shortly. Discounts are also available for multiple places for a limited period.

Alternatively, please leave your details in the form below.